Aclaris Therapeutics, Inc. (8AT.F)
Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
At close: 08:05AM CEST
| Previous Close | 1.2355 |
| Open | 1.2105 |
| Bid | 1.2415 x 0 |
| Ask | 1.2910 x 0 |
| Day's Range | 1.2105 - 1.2105 |
| 52 Week Range | 0.5900 - 11.8450 |
| Volume | |
| Avg. Volume | 95 |
| Market Cap | 86.965M |
| Beta (5Y Monthly) | 0.28 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.0100 |
| Earnings Date | Aug 05, 2024 - Aug 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 34.80 |
ZacksIs Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?
Here is how Aclaris Therapeutics (ACRS) and Adma Biologics (ADMA) have performed compared to their sector so far this year.
GlobeNewswireAclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 Million
- Non-Dilutive Transaction Strengthens Balance Sheet to Support Strategic Priorities -- $26.5 Million Upfront Plus Up to $5.0 Million Milestone - WAYNE, Pa., July 16, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the sale of a portion of Aclaris’ future royalty payments and certain milestones from Eli Lilly and Company (Lilly) on net sales
ZacksIs ADMA Biologics (ADMA) Stock Outpacing Its Medical Peers This Year?
Here is how Adma Biologics (ADMA) and Aclaris Therapeutics (ACRS) have performed compared to their sector so far this year.
© 2024 Yahoo. All rights reserved.